[{"id":"nogapendekin-alfa","kind":"drug","name":"Nogapendekin alfa inbakicept","route":"/drugs/nogapendekin-alfa/","commit":"9cbd69eefa","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for a fourth batch of thirty approved products","file":"src/data/spikes/urothelial.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"FDA label (DailyMed)\", url: \"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Nogapendekin%20alfa%20inbakicept\" }]"}]},{"id":"nogapendekin-alfa","kind":"drug","name":"Nogapendekin alfa inbakicept","route":"/drugs/nogapendekin-alfa/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/urothelial.ts","type":"changed","fields":[{"field":"tldr","before":"\"An engineered version of the immune-boosting protein IL-15, given with BCG into the bladder, approved in 2024 for early bladder cancer that BCG alone no longer controls.\"","after":"\"Nogapendekin alfa inbakicept is an engineered version of the immune-boosting protein IL-15, given with BCG into the bladder, approved in 2024 for early bladder cancer that BCG alone no longer controls.\""}]},{"id":"nogapendekin-alfa","kind":"drug","name":"Nogapendekin alfa inbakicept","route":"/drugs/nogapendekin-alfa/","commit":"06611b41fb","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: SCLC, mesothelioma, urothelial, RCC deep dives with structured outcomes, dosing, toxicity, regulatory events","file":"src/data/spikes/urothelial.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"brand"},{"field":"code"},{"field":"modality"},{"field":"status"},{"field":"tldr"},{"field":"summary"},{"field":"mechanism"},{"field":"mechanismSteps"},{"field":"dosing"},{"field":"toxicity"},{"field":"approvals"},{"field":"technologies"},{"field":"companies"},{"field":"cancers"},{"field":"trials"},{"field":"terms"}]}]